Home Cart Sign in  
Chemical Structure| 315704-66-6 Chemical Structure| 315704-66-6

Structure of PTC-209
CAS No.: 315704-66-6

Chemical Structure| 315704-66-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PTC-209 is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in the HEK293T cell line.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PTC-209

CAS No. :315704-66-6
Formula : C17H13Br2N5OS
M.W : 495.19
SMILES Code : CC1=C(C2=CSC(NC3=C(Br)C=C(OC)C=C3Br)=N2)N4C=CC=NC4=N1
MDL No. :MFCD02110649
InChI Key :XVOOCQSWCCRVDY-UHFFFAOYSA-N
Pubchem ID :1117196

Safety of PTC-209

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PTC-209

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Cal27 cells 10 µM 48 hours PTC-209 significantly inhibited cell proliferation and induced G1-phase cell cycle arrest and apoptosis Cancer Cell Int. 2017 Nov 21;17:107.
FaDu cells 10 µM 48 hours PTC-209 significantly inhibited cell proliferation and induced G1-phase cell cycle arrest and apoptosis Cancer Cell Int. 2017 Nov 21;17:107.
CP20 cells 100 nM 48 hours PTC-209 significantly increased LC3B-II and reduced SQSTM1 and BMI1 levels, indicating induction of autophagy Autophagy. 2016;12(4):659-70.
OVCAR4 cells 100 nM 48 hours PTC-209 significantly increased LC3B-II and reduced SQSTM1 and BMI1 levels, indicating induction of autophagy Autophagy. 2016;12(4):659-70.
ATRT-like cells 100, 50, 10, 5, 6.25, 1, 0.5, 0.1, 0.05, 0.01 µM 48 hours To test the effect of PTC-209 on the viability of ATRT-like cells, results showed that PTC-209 significantly reduced cell viability. Bioact Mater. 2023 Aug 12;31:136-150.
HCT116 cells 1.67 µM 72 hours PTC-209 showed anti-proliferative activity in HCT116 cells with an IC50 of 1.67 μM. J Exp Clin Cancer Res. 2019 Oct 22;38(1):422.
HT29 cells 1.36 µM 72 hours PTC-209 showed anti-proliferative activity in HT29 cells with an IC50 of 1.36 μM. J Exp Clin Cancer Res. 2019 Oct 22;38(1):422.
Human multiple myeloma cell lines (HMCLs) 0.01 –10 µM 96 hours PTC-209 significantly decreased the viability of all analysed human multiple myeloma cell lines with IC50 values <2 μM in six of eight HMCLs, and IC50 values were not reached in healthy donor peripheral blood mononuclear cells (PBMCs) and bone marrow stromal cells (BMSCs). J Hematol Oncol. 2016 Mar 2;9:17.
Human bone marrow stromal cells (BMSCs) 0.01 –10 µM 96 hours PTC-209 did not reach IC50 values in healthy donor peripheral blood mononuclear cells (PBMCs) and bone marrow stromal cells (BMSCs), indicating lower toxicity to normal cells. J Hematol Oncol. 2016 Mar 2;9:17.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice HNSCC xenograft model Subcutaneous injection 30 mg/kg Daily for 15 consecutive days PTC-209 significantly inhibited tumor growth, likely through Bmi1 inhibition and impaired cell proliferation Cancer Cell Int. 2017 Nov 21;17:107.
BALB/c Nude mice Subcutaneous tumor xenograft model Intraperitoneal injection 30 mg/kg Once daily for 24 days PTC-209 significantly inhibited subcutaneous tumor growth with no obvious toxicity. J Exp Clin Cancer Res. 2019 Oct 22;38(1):422.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.02mL

0.40mL

0.20mL

10.10mL

2.02mL

1.01mL

20.19mL

4.04mL

2.02mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories